Physician profile
Omar Ali
NPI 1568402188
$5,472.12
in general payments reported to CMS, 2019-2025
31 companies · $1,273 in 2025
The $1,273 reported for 2025 was more than what a typical Pediatric Endocrinology provider received nationally (typical 2025 total: $294).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $574 · 2020: $211 · 2021: $701 · 2022: $681 · 2023: $1,294 · 2024: $739 · 2025: $1,273.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,905 · Education: $23.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,905.28 |
| Education | $23.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,151.08 | 2019-2025 | Lupron Depot |
| Abbott Laboratories | $515.00 | 2021-2025 | Freestyle Libre 3 |
| Dexcom, INC. | $410.92 | 2019-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Tandem Diabetes Care, INC. | $293.14 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Sanofi-Aventis U.S. LLC | $286.36 | 2023-2025 | |
| Ascendis Pharma Endocrinology INC | $283.59 | 2022-2025 | Skytrofa |
| Novo Nordisk INC | $264.19 | 2020-2025 | Sogroya |
| Tolmar, INC. | $181.15 | 2023-2025 | Fensolvi |
| Ultragenyx Pharmaceutical INC. | $179.54 | 2020-2023 | |
| Pfizer INC. | $178.33 | 2022-2025 | |
| Medtronic, INC. | $154.96 | 2021-2025 | Minimed 780g |
| Insulet Corporation | $153.14 | 2019-2025 | Omnipod, Omnipod |
| Astrazeneca Pharmaceuticals LP | $110.17 | 2023 | Farxiga |
| Xeris Pharmaceuticals, INC. | $108.64 | 2021-2024 | Gvoke Hypopen |
| Rhythm Pharmaceuticals, INC. | $100.30 | 2021-2023 | Imcivree |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $83.88 | 2023-2025 | Crysvita |
| Biomarin Pharmaceutical INC. | $79.70 | 2021 | |
| Janssen Pharmaceuticals, INC | $73.24 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $67.13 | 2021 | |
| Soleno Therapeutics, INC. | $64.30 | 2025 | Vykat Xr |
| Vistapharm, INC. | $64.04 | 2021 | |
| Azurity Pharmaceuticals, INC. | $61.66 | 2023 | Triptodur |
| Neurocrine Biosciences, INC. | $41.06 | 2025 | |
| Lilly USA, LLC | $36.56 | 2021 | |
| Arbor Pharmaceuticals, INC. | $34.33 | 2019-2021 | |
| Avita Medical Americas, LLC | $28.54 | 2023 | Recell |
| Tolmar Pharmaceuticals, INC. | $23.96 | 2022 | |
| Endo Pharmaceuticals INC. | $21.22 | 2020 | |
| Lifescan, INC. | $18.17 | 2020 | |
| Glaxosmithkline, LLC. | $13.41 | 2021 | |
| Alexion Pharmaceuticals, INC. | $13.12 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Omar Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.